{
    "clinical_study": {
        "@rank": "14997", 
        "arm_group": [
            {
                "arm_group_label": "RIPC", 
                "arm_group_type": "Active Comparator", 
                "description": "Remote ischemic preconditioning (RIPC) protocol before coronary artery bypass surgery (CABG):\nafter induction of anesthesia and before surgery: 3 cycles of 5 minutes left upper arm ischemia by inflation of a blood pressure cuff to 200mmHg and 5 minutes of reperfusion Anesthesia is with isoflurane (0.7-0.8% end-tidal) +sufentanil"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "No Remote ischemic preconditioning (RIPC) protocol before coronary artery bypass surgery (CABG):\nafter induction of anesthesia and before surgery: the cuff is left uninflated"
            }
        ], 
        "brief_summary": {
            "textblock": "Remote ischemic preconditioning (RIPC) with transient upper limb ischemia/reperfusion\n      provides peri-operative myocardial protection, is safe and improves prognosis in patients\n      undergoing elective CABG surgery.\n\n      The signal transfer from limb to heart is unknown. Thus, the aim of this study is to\n      identify the pathways which transfer the cardioprotective signal from the\n      ischemic/reperfused extremity to the heart in humans undergoing surgical coronary\n      revascularization."
        }, 
        "brief_title": "Transfer of Cardioprotection During RIPC", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "CABG", 
        "detailed_description": {
            "textblock": "The investigators will obtain arterial blood samples before skin incision and 1-72 h after\n      the remote ischemic preconditioning protocol and analyze them biochemically. The\n      investigators focus on those ligands that have been previously implicated in conditioning\n      protocols at any organ. In addition, the investigators will use a bioassay system,\n      consisting of a Langendorff-perfused isolated heart with coronary occlusion/reperfusion and\n      infarct size by TTC staining as endpoint, and then expose this bioassay system to arterial\n      plasma obtained after the remote ischemic preconditioning stimulus or placebo. This approach\n      will allow us to further characterize any potential transfer signal candidate with a\n      pharmacological antagonist approach."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Consecutive patients > 18 years after written informed consent\n\n          -  elective, isolated CABG surgery with and without valvuloplastic surgery\n\n          -  two-stage cannulation, cardiopulmonary bypass\n\n          -  antegrade Bretschneider cardioplegia\n\n          -  mild hypothermia (32\u00b0C)\n\n          -  preoperative standard medication (statins, betablocker, aspirin)\n\n          -  standard anesthesia (see above)\n\n          -  intraoperative standard protocol (full heparinization with ACT, aprotinin, protamin)\n\n          -  postoperative standard protocol (500 mg aspirin after 2 h, low-dose heparin after 4\n             h)\n\n        Exclusion Criteria:\n\n        preoperative\n\n          -  prior percutaneous coronary intervention (PCI) within 6 weeks\n\n          -  any preoperative troponin I elevation\n\n          -  renal insufficiency (creatinine >200 \u00b5mol/l)\n\n          -  reoperation\n\n          -  emergency surgery\n\n          -  acute coronary syndrome (unstable angina, STEMI, NSTEMI) within 4 weeks\n\n          -  dual anti-platelet therapy (clopidogrel+aspirin)\n\n        intraoperative\n\n          -  harvesting of a. radialis\n\n          -  coronary thrombendarterectomy\n\n          -  complications (bypass-low flow/ -occlusion)\n\n          -  antithrombotic therapy (intraoperative clopidogrel + aspirin)\n\n          -  retrograde cardioplegia"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "332", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01956708", 
            "org_study_id": "RIPC-13-5507-BO"
        }, 
        "intervention": {
            "arm_group_label": "RIPC", 
            "description": "3 cycles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion", 
            "intervention_name": "RIPC", 
            "intervention_type": "Procedure", 
            "other_name": "RIPC: Remote ischemic preconditioning"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 7, 2013", 
        "location": {
            "contact": {
                "email": "markus.kamler@heh.uk-essen.de", 
                "last_name": "Markus Kamler, MD", 
                "phone": "+49-201-2802211"
            }, 
            "contact_backup": {
                "email": "petra.kleinbongard@uk-essen.de", 
                "last_name": "Petra Kleinbongard, PhD", 
                "phone": "+49-201-723-2763"
            }, 
            "facility": {
                "address": {
                    "city": "Essen", 
                    "country": "Germany", 
                    "zip": "4130"
                }, 
                "name": "Herzzentrum Essen - Huttrop gGmbH, Einrichtung des Universit\u00e4tsklinikums Essen"
            }, 
            "investigator": {
                "last_name": "Markus Kamler, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "markus.kamler@uk-essen.de", 
            "last_name": "Markus Kamler, MD", 
            "phone": "+49-201-2802211"
        }, 
        "overall_contact_backup": {
            "email": "petra.kleinbongard@uk-essen.de", 
            "last_name": "Petra Kleinbongard, PhD", 
            "phone": "+49-201-723-2763"
        }, 
        "overall_official": {
            "affiliation": "Herzzentrum Essen - Huttrop gGmbH, Einrichtung des Universit\u00e4tsklinikums Essen,  Essen, Germany", 
            "last_name": "Markus Kamler, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Ethics Commission", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Myocardial protection: cumulative postoperative troponin I release", 
            "safety_issue": "Yes", 
            "time_frame": "72 h, postoperatively"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01956708"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University Hospital, Essen", 
            "investigator_full_name": "Prof. Dr. med. Markus Kamler", 
            "investigator_title": "Prof. Dr. med. Markus Kamler", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "All-cause mortality", 
                "safety_issue": "Yes", 
                "time_frame": "30 days and 1 year after CABG surgery and after complete follow-up"
            }, 
            {
                "measure": "Major adverse cardiac and cerebrovascular events (MACCE)", 
                "safety_issue": "Yes", 
                "time_frame": "30 days and 1 year after CABG surgery  after complete follow-up"
            }, 
            {
                "measure": "renal function (creatinine and eGFR)", 
                "safety_issue": "Yes", 
                "time_frame": "72 h, postoperatively"
            }, 
            {
                "measure": "Cardioprotective factors released into circulating blood", 
                "safety_issue": "No", 
                "time_frame": "before skin incision versus 1-72 h after RIPC"
            }
        ], 
        "source": "University Hospital, Essen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital, Essen", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}